Intravenous Infusions is trading 9.09% down at GHS 0.40 after continued profit-taking following its speculative July 30 rally to GHS 0.86.
- Selling pressure has persisted across several consecutive sessions, with the stock falling from GHS 0.78 on August 3 to GHS 0.40 during the August 14 session.
- Recent coverage highlights weaker first-half revenue despite improved margins.
- Investors appear to be locking in gains after the sharp July advance, while broader markets are broadly flat, offering little support for the decline.